Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

Abstract: The present invention discovered that a mammalian TRPM8 binds to calmodulin. The present invention provides a polypeptide complex comprising a cold-menthol receptor (TRPM8) or an active fragment or derivative of TRPM8 and a calmodulin or an active fragment or derivative of calmodulin, and the uses of the polypeptide complex.

Abstract: A casing treatment for a fan or compressor stage 10 of a gas turbine engine comprises circumferential grooves 16A, 16B, 16C, 16D and 16E which extend in a series disposed between the leading edges 20 and trailing edges 22 of blades 6 of a fan or compressor stage 10. The grooves 16 vary in depth d in order to optimise the stall margin of the fan or compressor stage 10 while preserving peak efficiency.

Abstract: A method of connecting three-dimensional structured meshes to form a conformal mesh, for solutions of flow problems, including: forming an interface by overlaying surfaces of two structured meshes; defining an interface set of mesh points in the interface; merging mesh points in the interface set that are within a predetermined distance of each other and projecting mesh points of one mesh in the interface that are within a predetermined distance of a line of the other mesh; generating an interface layer in the form of an unstructured mesh; and inserting a node at the centre of each hexahedra, and producing an unstructured layer of cells between the two structured meshes by joining the nodes to the mesh points of the interface layer.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.

Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.

Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.

Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.

Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.

Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.

Abstract: A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing a neve isozyme of the cyclooxygenase enzyme, herein named as human cyclooxygenase 3. The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays, gene therapy, and screening assays.

Abstract: DNAs encoding human voltage gated sodium channel ?1A subunit have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing a novel canine cold- and menthol-sensitive receptor, herein named as canine CMR1 (cCMR1). The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays and screening assays.